City Center Advisors LLC Buys New Shares in Axon Enterprise, Inc $AXON

City Center Advisors LLC bought a new stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) during the 2nd quarter, Holdings Channel reports. The firm bought 514 shares of the biotechnology company’s stock, valued at approximately $426,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Axon Enterprise by 2.2% in the first quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock valued at $4,540,005,000 after acquiring an additional 185,571 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of Axon Enterprise by 15.9% in the first quarter. Alliancebernstein L.P. now owns 1,284,935 shares of the biotechnology company’s stock valued at $675,812,000 after acquiring an additional 175,890 shares in the last quarter. Westfield Capital Management Co. LP lifted its position in shares of Axon Enterprise by 29.8% in the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock valued at $487,977,000 after acquiring an additional 212,931 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Axon Enterprise by 58,725.5% in the first quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company’s stock valued at $402,210,000 after acquiring an additional 763,431 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Axon Enterprise by 1.2% in the first quarter. Northern Trust Corp now owns 725,720 shares of the biotechnology company’s stock valued at $381,692,000 after acquiring an additional 8,794 shares in the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Stock Up 0.7%

Shares of NASDAQ:AXON opened at $756.13 on Friday. Axon Enterprise, Inc has a 52-week low of $375.71 and a 52-week high of $885.91. The stock has a market cap of $59.36 billion, a P/E ratio of 186.70, a price-to-earnings-growth ratio of 27.57 and a beta of 1.40. The business’s 50 day moving average is $761.10 and its 200 day moving average is $686.46. The company has a quick ratio of 2.71, a current ratio of 2.95 and a debt-to-equity ratio of 0.63.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The company had revenue of $668.54 million for the quarter, compared to analysts’ expectations of $641.77 million. During the same quarter in the prior year, the firm earned $1.20 earnings per share. Axon Enterprise’s revenue was up 32.6% compared to the same quarter last year. Axon Enterprise has set its FY 2025 guidance at EPS. Sell-side analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on AXON. Wolfe Research began coverage on Axon Enterprise in a research report on Monday, July 7th. They issued an “outperform” rating on the stock. UBS Group reaffirmed a “neutral” rating and issued a $840.00 target price (up from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Raymond James Financial restated an “outperform” rating and set a $855.00 price objective (up from $645.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Northland Securities set a $800.00 price objective on Axon Enterprise in a research report on Tuesday, August 5th. Finally, Craig Hallum upgraded Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 price objective on the stock in a research report on Tuesday, August 5th. Thirteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $837.69.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, CAO Jennifer H. Mak sold 75 shares of the stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $723.50, for a total transaction of $54,262.50. Following the sale, the chief accounting officer owned 15,080 shares of the company’s stock, valued at approximately $10,910,380. This trade represents a 0.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Joshua Isner sold 15,919 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $746.26, for a total value of $11,879,712.94. Following the sale, the president directly owned 238,379 shares in the company, valued at $177,892,712.54. This trade represents a 6.26% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 44,790 shares of company stock worth $34,304,947. 4.40% of the stock is currently owned by company insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.